GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Deferred Policy Acquisition Costs

Pharming Group (XAMS:PHARM) Deferred Policy Acquisition Costs


View and export this data going back to 1998. Start your Free Trial

What is Pharming Group Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Pharming Group Business Description

Industry
Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.